ACAD vs PTGX
ACADIA Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
65
Buy
| Metric | ACAD | PTGX |
|---|
| AI Score |
69
|
65
|
| Price |
$29.41
|
$148.25
|
| P/E Ratio |
13.07×
|
121.74×
|
| ROE |
31.9%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
99.9%
|
| Debt / Equity |
0.06×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
68.1
|
| Beta |
0.845
|
1.794
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus PTGX.
ACAD leads by 4 points.
ACAD scores 69/100 (Buy) versus PTGX at 65/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical